![Partnering-banner.jpg](https://images.squarespace-cdn.com/content/v1/639a279aa2f7e15993210ea2/1701867423263-8TYL8V8B55BU1VY1WLXU/Partnering-banner.jpg)
CURRENT PARTNERSHIPS
Click below to learn more
Partner with Us
We are currently interested in collaboration opportunities related to our liver disease portfolio and programs for outlicensing.
To initiate a partnering discussion, visit us at an upcoming event or email us at partnering@bostonpharmaceuticals.com
![AdobeStock_340532559.jpeg](https://images.squarespace-cdn.com/content/v1/639a279aa2f7e15993210ea2/1671047076159-NO190LDPKGVHP2ZL48YZ/AdobeStock_340532559.jpeg)
OUTLICENSING OPPORTUNITIES
Boston Pharmaceuticals is committed to working with the best partners to bring medicines to patients. We currently have multiple collaboration opportunities, including the programs available for out-licensing listed below:
Compound: BOS161721 (avizakimab)
IL-21 Mab for Lupus
Pre-Clin
P1
P2
P3
Compound: BOS-475
BETi for Psoriasis (topical)
Pre-Clin
P1
P2
P3
Compound: BOS-857
Furin Inhibitors for Fibrosis Resolution
Pre-Clin
P1
P2
P3